Somatic C-KIT D816V mutation in core binding factor acute myeloid leukemia (CBF-AML) and its association with laboratory features
Main Article Content
Abstract
Core-binding factor acute myeloid leukemia (CBF-AML) is a group of diseases with a good prognosis, although some patients in this group have a poor outcome. This pushes researchers to look for other prognostic factors to be able to more accurately assess the patient's condition. Besides gene mutations such as FLT3-ITD, FLT3-TKD, NPM1... C-KIT mutation is also of interest in research. A close relationship between C-KIT mutations and disease prognosis has not been clearly established. However, when analyzing in detail the mutation locations, C-KIT D816V mutation was found to be a potential prognostic factor. Among 98 AML patients, we found 20 CBF-AML patients, of which 2% carried the C-KIT D816V mutation. CBF-AML patients with the C-KIT D816V mutation exhibited more severe anemia, thrombocytopenia and higher white blood cell count, blast rate when compared with other group.
Article Details
Keywords
CFB-AML, C-KIT D816V, abnormal chromosomes
References
2. Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2009;4(2):77-82. doi:10.1007/s11899-009-0011-8
3. Ishikawa Y, Kawashima N, Atsuta Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4(1):66-75. doi:10.1182/bloodadvances.2019000709
4. Dhandapani K, Shankaralingappa S, Sundarajan U, et al. C-Kit and Flt3 mutation status in acute myeloid leukaemia with cytogenetic correlation and prognosis: A series of 75 cases. IP Journal of Diagnostic Pathology and Oncology. 8(4):217-221. doi:10.18231/j.jdpo.2023.051
5. Trần Thu Thuỷ, Hoàng Thị Hồng, Đỗ Hoàng Hải, và cs. Bất thường di truyền và mối liên quan với đáp ứng điều trị ở bệnh nhi lơ xê mi cấp dòng tủy điều trị tại Viện Huyết học - Truyền máu Trung ương. Tạp chí Nghiên cứu Y học. 2023;170(9):152-161. doi:10.52852/tcncyh.v170i9.1923
6. Li EW, Tran NYK, McCulloch D, et al. FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia. Int J Mol Sci. 2024;25(11):5771. doi:10.3390/ijms25115771
7. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468. doi:10.1182/blood-2005-09-3640
8. Kumar CC. Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia. Genes Cancer. 2011;2(2):95-107. doi:10.1177/1947601911408076
9. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799. doi:10.1182/blood-2005-04-1466